Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Corrigendum Free access | 10.1172/JCI125039

PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy

Dmitriy Zamarin, Jacob M. Ricca, Svetlana Sadekova, Anton Oseledchyk, Ying Yu, Wendy M. Blumenschein, Jerelyn Wong, Mathieu Gigoux, Taha Merghoub, and Jedd D. Wolchok

Find articles by Zamarin, D. in: PubMed | Google Scholar

Find articles by Ricca, J. in: PubMed | Google Scholar

Find articles by Sadekova, S. in: PubMed | Google Scholar

Find articles by Oseledchyk, A. in: PubMed | Google Scholar

Find articles by Yu, Y. in: PubMed | Google Scholar

Find articles by Blumenschein, W. in: PubMed | Google Scholar

Find articles by Wong, J. in: PubMed | Google Scholar

Find articles by Gigoux, M. in: PubMed | Google Scholar

Find articles by Merghoub, T. in: PubMed | Google Scholar

Find articles by Wolchok, J. in: PubMed | Google Scholar

Published October 2, 2018 - More info

Published in Volume 128, Issue 11 on November 1, 2018
J Clin Invest. 2018;128(11):5184–5184. https://doi.org/10.1172/JCI125039.
Copyright © 2018, American Society for Clinical Investigation
Published October 2, 2018 - Version history
View PDF

Related article:

PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
Dmitriy Zamarin, … , Taha Merghoub, Jedd D. Wolchok
Dmitriy Zamarin, … , Taha Merghoub, Jedd D. Wolchok
Research Article Immunology Oncology

PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy

  • Text
  • PDF
Abstract

Intralesional therapy with oncolytic viruses (OVs) leads to the activation of local and systemic immune pathways, which may present targets for further combinatorial therapies. Here, we used human tumor histocultures as well as syngeneic tumor models treated with Newcastle disease virus (NDV) to identify a range of immune targets upregulated with OV treatment. Despite tumor infiltration of effector T lymphocytes in response to NDV, there was ongoing inhibition through programmed death ligand 1 (PD-L1), acting as a mechanism of early and late adaptive immune resistance to the type I IFN response and T cell infiltration, respectively. Systemic therapeutic targeting of programmed cell death receptor 1 (PD-1) or PD-L1 in combination with intratumoral NDV resulted in the rejection of both treated and distant tumors. These findings have implications for the timing of PD-1/PD-L1 blockade in conjunction with OV therapy and highlight the importance of understanding the adaptive mechanisms of immune resistance to specific OVs for the rational design of combinatorial approaches using these agents.

Authors

Dmitriy Zamarin, Jacob M. Ricca, Svetlana Sadekova, Anton Oseledchyk, Ying Yu, Wendy M. Blumenschein, Jerelyn Wong, Mathieu Gigoux, Taha Merghoub, Jedd D. Wolchok

×

Original citation: J Clin Invest. 2018;128(4):1413–1428. https://doi.org/10.1172/JCI98047

Citation for this corrigendum: J Clin Invest. 2018;128(11):5184. https://doi.org/10.1172/JCI125039

Jedd D. Wolchok’s conflict-of-interest information was incomplete. The omitted statement is below.

JDW has acted as a consultant for Adaptive Biotechnologies, Advaxis, Amgen, Apricity, Array BioPharma, Ascentage Pharma, BeiGene, Bristol-Myers Squibb, Celgene, Chugai Pharmaceutical Co., Elucida Oncology Inc., Eli Lilly and Company, F-Star, Genentech, Imvaq Therapeutics Corp., Kleo Pharmaceuticals, MedImmune, Merck, Neon Therapuetics, Ono Pharmaceutical Co., Polaris Pharma, Polynoma, PsiOxus Therapeutics, PureTech Health, Recepta Biopharma SA, Trieza Therapeutics, Sellas Life Sciences, Serametrix Immune Monitoring, Surface Oncology, and Syndax; has received research support from Bristol-Myers Squibb, MedImmune, Merck, Genentech; and has equity in Potenza Therapeutics (cofounder), Tizona Therapeutics (cofounder), Adaptive Biotechnologies, Elucida Oncology Inc., Imvaq Therapeutics Corp., BeiGene, and TriEnza.

The authors regret the error.

Footnotes

See the related article at PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.

Version history
  • Version 1 (October 2, 2018): Electronic publication
  • Version 2 (November 1, 2018): Print issue publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts